Trulicity Injection, Solution
Product Images NDC 50090-3483

Product Visual Gallery

This gallery contains 47 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 50090-3483). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903483)

Trulicity (Dulaglutide) Injection 1.5 mg/0.5 mL, solution for subcutaneous use, single-dose pen packaging by A-S Medication Solutions. The label indicates storage instructions including refrigeration at 36 to 46°F and a warning that the product must be protected from light and used in original carton. The package contains 4 single-dose pens.*

FDA Label Image

Label Image (Lbl500903484)

A label for Trulicity Dulaglutide Injection 0.75 mg/0.5 mL manufactured by A-S Medication Solutions, Libertyville, IL. The label mentions the product code 6798-0 and the NDC number 50090-3484-0, indicating it contains 4 single-dose pens. Storage instructions advise keeping the unopened container between 36 and 46 degrees Fahrenheit without freezing and storing in the original container until administration.*

FDA Label Image

Logo (Logo)

FDA Label Image

Qr Code (Qr V1)

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites V1)

Illustration showing possible injection sites for a subcutaneous injection on a human figure. Front view highlights areas on the abdomen and thighs, while back view highlights areas on the upper arms and lower back sides.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites V1)

Illustration showing injection sites on the human body for subcutaneous administration of Trulicity (dulaglutide). Highlighted areas include the upper arms, stomach area, and front and outer sides of the thighs, depicted on front and back views of the body.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites V1)

Instructional diagram showing preferred subcutaneous injection sites on a human body for Trulicity (Dulaglutide) injection. The front view highlights the abdomen, front thighs, and outer upper arms, while the back view indicates areas on the upper outer arms and the lower back near the hips, recommended for injections.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites V1)

An illustration showing injection site locations for subcutaneous administration of Trulicity (Dulaglutide). The green shaded areas on front and back views of a human figure indicate suitable injection sites: abdomen, outer upper arms, and front and outer thighs.*

FDA Label Image

Figure (Trulicity Ifu Check V1)

FDA Label Image

Exclamation (Trulicity Ifu Exclamation V1)

Trulicity 1.5 mg/0.5 mL injection pen packaging label. The label shows the brand name Trulicity with the active ingredient Dulaglutide, indicating a subcutaneous injection dosage form. The package is associated with A-S Medication Solutions as the labeler. The label is primarily white with purple and orange accents and includes vial information and dosing instructions in small text.*

FDA Label Image

Figure (Trulicity Ifu Expiration Location V2)

An illustration showing a subcutaneous injection pen with a red arrow pointing to the expiration date window on the pen, highlighting where the expiration date is located.*

FDA Label Image

Figure (Trulicity Ifu Inspect V1)

FDA Label Image

Locked (Trulicity Ifu Locked V1)

Trulicity 0.75 mg/0.5 mL and 1.5 mg/0.5 mL subcutaneous injection solution prefilled pens shown in a white and purple blister package. The label indicates Dulaglutide as the active ingredient and the product is labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Prepare V1)

FDA Label Image

Figure (Trulicity Ifu Remove V1)

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F2 V3)

An instructional illustration showing a hand holding a prefilled pen injector with green cap and purple and yellow labeling, aligned above a black circular component held by another hand. A downward arrow indicates the action of pressing the injector onto the component, suggesting a step in preparing or using the injection device for subcutaneous administration.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F3 V3)

An instructional diagram showing a person holding a prefilled injection pen with both hands, preparing to administer a subcutaneous injection. The illustration emphasizes proper handling and injection technique.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F4 V3)

An instructional illustration showing hands holding a Trulicity prefilled injection pen at a 90-degree angle to the skin, with an inset close-up highlighting a dosage indicator. The diagram indicates holding the pen steady for 5-10 seconds during a subcutaneous injection to ensure full dose delivery.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F5 V3)

An instructional illustration showing a hand holding a prefilled Trulicity injection pen being disposed into a biohazard sharps container. The container has a biohazard symbol indicating appropriate disposal of used injection devices.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)

An instructional diagram of a Trulicity (Dulaglutide) injection pen showing labeled parts including the Injection Button, Lock Ring, Indicator, Lock/Unlock symbols, Medicine reservoir, Clear Base, and Base Cap, providing a clear visual guide to the pen's components and orientation.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen V3)

Trulicity injection pen for subcutaneous use, containing Dulaglutide in a 1.5 mg/0.5 mL dosage form. The pen is primarily white with a yellow and purple label section and features a green cap. It is labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F2 V3)

An instructional diagram showing a hand holding a prefilled injection pen (likely Trulicity) with a green cap being aligned or connected to another component held by the opposite hand, with an arrow indicating the downward motion for attachment or assembly.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F3 V3)

An instructional illustration showing a person administering a subcutaneous injection using a pre-filled pen device, presumably for Trulicity (dulaglutide) injection. The image emphasizes the injection site on the abdomen and the hand positioning on the device.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F4 V3)

An instructional illustration showing hands holding a Trulicity prefilled injection pen, demonstrating injection technique with a 5-10 seconds timing indicator. A close-up inset highlights the pen's window to check the liquid level or dose indicator before administration, depicting proper use of the subcutaneous injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F5 V3)

An illustration showing a hand holding a prefilled injection pen over a medical sharps disposal container marked with a biohazard symbol, demonstrating proper disposal of the injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)

An instructional diagram of the Trulicity injection pen showing labeled parts: Injection Button, Lock Ring, Indicator with Lock/Unlock symbols, Medicine area, Clear Base, and Base Cap, with directional arrows indicating the Top and Bottom/Needle End of the pen.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen V3)

Trulicity (Dulaglutide) injection, solution in a single-dose prefilled pen syringe. The device has a white body with a blue and purple label band, green cap, and a gray needle cover, designed for subcutaneous administration. Labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F2 V1)

An instructional illustration showing hands holding a Trulicity injection pen solution. The image depicts removing the cap from the injection pen, indicated by a downward arrow, within a red-bordered box. The illustration is intended to guide proper preparation or use of the subcutaneous injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F3 V1)

An instructional illustration shows a person using their hands to twist or activate the green cap on a syringe or injection device, set against a gray pants background. The image likely demonstrates a step in preparing the Trulicity injection for use.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F4 V1)

Illustration showing step-by-step instructions for use of an injection pen for Trulicity (Dulaglutide). It depicts a person administering a subcutaneous injection, highlighting a 5-10 second wait time and indicating that the injection is complete when the gray plunger becomes visible through a window on the device.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F5 V1)

Illustration showing a hand holding a prefilled syringe upright above a biohazard sharps container, demonstrating proper disposal of the injection device. The syringe contains a liquid medication, likely Trulicity (Dulaglutide) injection, solution for subcutaneous use.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen Parts V1)

An instructional diagram of a Trulicity (dulaglutide) injection pen showing labeled parts including the injection button, lock ring, indicator, lock/unlock symbols, medicine area, clear base, and base cap. The diagram also indicates the top and bottom/needle end of the pen to guide users on its components and orientation.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen V1)

Trulicity injection pen for subcutaneous use is shown, containing Dulaglutide. The pen has a clear barrel with visible liquid inside, a white and green cap on one end, and a black protective cover on the other end. The label features a purple stripe and a space for dosing information. The product is labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F2 V1)

An instructional illustration showing a hand holding a Trulicity autoinjector pen with another hand removing or attaching a needle cap. The image includes directional arrows indicating the motion involved in preparing the injection device for use.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F3 V1)

Illustration showing a person preparing a subcutaneous injection using a pen device. The person is removing the cap from the pen by twisting it, demonstrating the step needed before administration of the medication injection solution.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F4 V1)

An instructional illustration showing the proper technique for administering a subcutaneous injection with a prefilled syringe. A close-up highlights that the injection is complete when the gray plunger becomes visible. The timing of 5 to 10 seconds for the injection is also indicated.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F5 V1)

An illustration showing a hand holding a prefilled syringe above a biohazard sharps disposal container, indicating proper disposal of the injection device. The syringe is likely for subcutaneous injection, consistent with the drug Trulicity (Dulaglutide).*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)

An instructional diagram of the Trulicity injection pen showing labeled parts including the injection button at the top, lock ring, indicator with lock/unlock symbols, medicine visible inside, clear base near the needle end, and the black base cap at the bottom.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen V1)

Trulicity 0.75 mg/0.5 mL subcutaneous injection solution in a prefilled pen. The pen is predominantly white with a green tip and green and red indicators near the top, and a transparent medication window near the left end. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Unfold V1)

An instructional diagram showing a folded paper or leaflet being unfolded and laid flat. The text instructs to read both sides for full instructions, indicating it is likely part of patient information or medication directions.*

FDA Label Image

Unlocked (Trulicity Ifu Unlock V1)

Trulicity 0.75 mg/0.5 mL and 1.5 mg/0.5 mL injection, solution for subcutaneous use, displayed in purple packaging. The label shows the proprietary name Trulicity, the nonproprietary name Dulaglutide, and the labeler A-S Medication Solutions. The box includes illustrations of the injection pen device and information about its dual strength options.*

FDA Label Image

Figure 1 (Trulicity Pi F1 V2)

A pharmacokinetic (PK) ratio and 90% confidence interval plot showing the effects of intrinsic factors including weight, age, sex, race, and levels of renal and hepatic impairment on the area under the curve (AUC) and maximum concentration (Cmax) of the drug. The x-axis represents the ratio relative to reference values, with values ranging from 0.0 to 2.0.*

FDA Label Image

Figure 2 (Trulicity Pi F2 V2)

A forest plot chart displaying the pharmacokinetic ratios (AUC and Cmax) with 90% confidence intervals for various coadministered drugs relative to a reference. The X-axis represents the ratio relative to reference from 0.0 to 2.0. The coadministered drugs listed include Lisinopril, Metoprolol, Digoxin, Norelgestromin, Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin. Each drug shows plotted points and intervals for both AUC and Cmax parameters.*

FDA Label Image

Figure 3 (Trulicity Pi F3 V1)

A line graph comparing LS mean HbA1c (%) over 52 weeks post-randomization for Trulicity injection at 0.75 mg and 1.5 mg, Sitagliptin 100 mg, and placebo. The graph shows a trend of decreasing HbA1c levels, with Trulicity 1.5 mg and 0.75 mg showing greater reduction compared to Sitagliptin and placebo.*

FDA Label Image

Figure 5 (Trulicity Pi F4 V1)

A line graph showing the mean HbA1c percentage over 26 weeks post-randomization for Trulicity injection at doses 0.75 mg and 1.5 mg, compared to Exenatide and placebo. The x-axis represents weeks post-randomization, and the y-axis shows LS Mean HbA1c (%). The graph includes a table of subject numbers across groups.*

FDA Label Image

Figure 6 (Trulicity Pi F5 V1)

A line graph comparing the percentage of patients with an event over time (up to 6 years) for Dulaglutide versus placebo. The x-axis represents years from randomization, and the y-axis shows patients with an event (%). Patient numbers at risk for both groups are listed below the x-axis. Dulaglutide shows a slightly lower event rate than placebo, with a hazard ratio (HR) of 0.88 (95% CI [0.79, 0.99]).*

FDA Label Image

Figure 4 (Trulicity Pi F6 V1)

A line graph depicting mean HbA1c (%) over weeks post-randomization for Trulicity injection solution in 1.5 mg, 3 mg, and 4.5 mg doses. The x-axis shows weeks from baseline (B) to 36, and the y-axis shows mean HbA1c percentage. The graph includes a legend identifying each dose group. A data table below the graph lists the number of subjects with observed data at baseline and week 36 for each dose group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.